[Effects of percutaneous coronary intervention on cardiac function in ischemic cardiomyopathy patients with different

X F Zheng1, L M Wu2, L L Chen2

  • 1Department of Cardiology, the third Affiliated Hospital of Fujian Medical University, Fuzhou 350108, China.

Zhonghua Yi Xue Za Zhi
|September 25, 2020
PubMed

Insights

Percutaneous coronary intervention (PCI) improves outcomes for ischemic cardiomyopathy patients with left ventricular ejection fraction >35%, but not those with LVEF ≤35%. Lower preoperative LVEF independently predicts acute left ventricular failure post-PCI.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Heart Failure Research

Background:

  • Ischemic cardiomyopathy (ICM) significantly impacts left ventricular (LV) function and remodeling.
  • Percutaneous coronary intervention (PCI) is a key revascularization strategy for ICM patients.
  • The clinical impact of PCI on LV remodeling and major adverse cardiovascular and cerebrovascular events (MACE) in ICM patients with varying LVEF and low SYNTAX scores requires further evaluation.

Purpose of the Study:

  • To assess the clinical impact of PCI on LV myocardial remodeling and MACE in ICM patients with SYNTAX score ≤22.
  • To analyze outcomes based on preoperative left ventricular ejection fraction (LVEF) categories: ≥50%, 36%-49%, and ≤35%.

Main Methods:

  • A cohort of 191 ICM patients undergoing PCI were categorized by preoperative LVEF.
  • Clinical outcomes, including MACE and LV remodeling parameters (LVEF, LV end-diastolic volume), were assessed at 12-month follow-up.
  • Multivariate analysis was used to identify predictors of adverse events.

Main Results:

  • While MACE incidence was similar across groups (P=0.231), acute left ventricular failure was significantly higher in the LVEF ≤35% group (22.9%, P=0.01).
  • Preoperative LVEF ≤35% was an independent predictor of acute left ventricular failure (OR=2.696, P=0.030).
  • PCI significantly improved LV ejection fraction and reduced LV end-diastolic volume and left atrium size at 1 year, with significant differences in remodeling parameters across LVEF groups.

Conclusions:

  • PCI improves prognosis in ICM patients with LVEF >35% (SYNTAX score ≤22) but offers limited benefit for those with LVEF ≤35%.
  • Preoperative LVEF is a crucial predictor of acute left ventricular failure post-PCI in this population.
  • Postoperative LV remodeling and systolic function are closely correlated with preoperative LVEF.

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
272
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
176
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
234
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
132
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
118
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
94